Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583270 | 0.88 | KDM4E (0.64) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL28652484 | 0.84 | KDM4E (0.56) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL20488880 | 0.84 | KDM4E (0.55) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL1291177 | 0.83 | KDM4E (0.58) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL12837985 | 0.83 | KDM4E (0.58) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL23684584 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL30260171 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL20608281 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KDM4EL3MBTL1LMNACYP1A2 | |
| SCHEMBL568182 | 0.81 | KDM4E (0.56) | ALDH1A1KDM4EL3MBTL1CA1CA2 | |
| SCHEMBL31414452 | 0.81 | KDM4E (0.79) | ALDH1A1KDM4EL3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10343999-B2 | Method for synthesizing enantiomerically pure N-(pyridin-4-yl)-2-hydroxy-alkylamide derivatives | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-09 | — | — | US | disclosed |
| US-10343999-B2 | Method for synthesizing enantiomerically pure N-(pyridin-4-yl)-2-hydroxy-alkylamide derivatives | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-09 | — | — | US | disclosed |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190010124-A1 | METHOD FOR SYNTHESIZING ENANIOMERICALLY PURE N-(PYRIDIN-4-YL)-2-HYDROXY-ALKYLAMIDE DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-01-10 | — | — | US | disclosed |
| EP-3383850-A1 | METHOD FOR SYNTHESISING ENANTIOMERICALLY PURE N-(PYRIDIN-4-YL)-2-HYDROXY-ALKYLAMIDE DERIVATIVES | Galderma Research & Development (FR) | 2018-10-10 | — | — | EP | disclosed |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
| EP-3194369-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | Verseon Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017092977-A1 | METHOD FOR SYNTHESISING ENANTIOMERICALLY PURE N-(PYRIDIN-4-YL)-2-HYDROXY-ALKYLAMIDE DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-06-08 | — | — | WO | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2417120-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SERPINE1, PRSS1, SPINT2 | ALDH1A1 3248/4885KDM4E 1769/4885L3MBTL1 2923/4885 |
| US-10189810-B2 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | SERPINE1, PRSS1, SPINT2 | ALDH1A1 3248/4885KDM4E 1769/4885L3MBTL1 2923/4885 |
| US-20190010124-A1 | METHOD FOR SYNTHESIZING ENANIOMERICALLY PURE N-(PYRIDIN-4-YL)-2-HYDROXY-ALKYLAMIDE DERIVATIVES | NAAA, PAH, HACL2 | ALDH1A1 653/4885KDM4E 1559/4885L3MBTL1 4827/4885 |
| US-10343999-B2 | Method for synthesizing enantiomerically pure N-(pyridin-4-yl)-2-hydroxy-alkylamide derivatives | HACL2, NAAA, CYP1A2 | ALDH1A1 307/4885KDM4E 1567/4885L3MBTL1 4831/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ALDH1A1 876/4885KDM4E 3679/4885L3MBTL1 3459/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | ALDH1A1 664/4885KDM4E 3566/4885L3MBTL1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.